Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure
David Clark,1 Paul Karpecki,2 Anne Marie Salapatek,3 John D Sheppard,4 Todd C Brady1 1Aldeyra Therapeutics, Lexington, MA, USA; 2Kentucky Eye Institute, Lexington, KY, USA; 3Cliantha Research, Mississauga, ON, Canada; 4Virginia Eye Consultants, Norfolk, VA, USACorrespondence: Todd C BradyAldeyra The...
Main Authors: | Clark D, Karpecki P, Salapatek AM, Sheppard JD, Brady TC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-01-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/reproxalap-improves-signs-and-symptoms-of-allergic-conjunctivitis-in-a-peer-reviewed-fulltext-article-OPTH |
Similar Items
-
The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis
by: Starr CE, et al.
Published: (2023-12-01) -
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
by: McMullin D, et al.
Published: (2021-09-01) -
Birch allergen challenges in allergic conjunctivitis using standard conjunctival allergen challenge and environmental exposure chamber
by: Alina Gherasim, et al.
Published: (2021-08-01) -
Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy
by: O. Pfaar, et al.
Published: (2020-07-01) -
Multiple Allergen Simultaneous Test-Immunoblot Assay for Immunoglobulin E Detection in Patients with Isolated Allergic Conjunctivitis
by: Jung Yeob Han, et al.
Published: (2021-03-01)